# US 10,479,814 B2 · Adenosine receptor activation reagent and the uses of thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,479,814 B2
- Document ID: US10479814B2
- Status: Granted
- Kind: B2
- Application number: 15/700,824
- Filed: 2017-09-11
- Published: 2017-12-28
- Granted: 2019-11-19
- Earliest claimed: 2014-07-27
- Assignees: Zhejiang Subtropical Crops Research Institute
- Applicants: Zhejiang Subtropical Crops Research Institute
- Inventors: Yiqiu Chai; Bichun Zhu; Xiuxiu Peng; Yiwei Jin
- Web page: https://patentgrep.com/patent/US10479814B2

## CPC

- C07H 19/16: Purine radicals
- C07H 19/167: with ribosyl as the saccharide radical
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/36: Opioid-abuse
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to application of N(6)-(2-hydroxyethyl)-adenosine (HEA) and its derivatives as an adenosine A1 receptor agonist in preparation of drug or food, the HEA and its derivatives are used in treatment of diseases relating to adenosine receptor regulator, such as insomnia, pain, convulsion, apoplexia, Parkinson's disease, opioid drug addiction and kidney ischemia reperfusion injury etc. The present invention provides a new method for treatment of the diseases relating to nervous system and kidney.

## Claims

### Claim 1

A method for treating a condition comprising administering N(6)-(2-hydroxyethyl)-adenosine (HEA) to a subject, wherein the condition is convulsion, pain, apoplexia, Parkinson's disease, or opioid drug addiction receptor; said HEA is administered in the amount of 10-15 mg/kg of subject body weight and treats the condition via the adenosine A1 receptor.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said HEA is derived from the group consisting of Cordyceps, Cordyceps militaris, Paecilomyces cicadae fungus and culture extract of the fungus.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said HEA is derived from the group consisting of Cordyceps cicadae, Cordyceps militaris, Cordyceps sinensis and extract of its artificial culture.